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hemodialysis (5,6) and 10 -12 mmol/day by peritoneal dialysis (7) . Thus, most well-nourished patients are in positive phosphorus balance. Consequently, the use of phosphorus binders is necessary for lowering serum phosphorus levels in these patients. Approximately 95% of dialysis patients use phosphorus binders to reduce dietary phosphorus absorption and achieve serum phosphorus control. Aluminum hydroxide (AH) and calcium salts were both commonly used as phosphorus binders; calcium salts are still in use at present. However, these traditional phosphorus binders lead to serious side effects, such as aluminum toxicity (8, 9) and an increased incidence of hypercalcemia (10, 11) , both of which limit their use. Moreover, hypercalcemia restricts the use of vitamin D to control serum parathormone levels (12) . Sevelamer hydrochloride (SH) is a nonabsorbed phosphorus-binding polymer that does not contain aluminum or calcium. The efficacy of SH in lowering serum phosphorus levels has been demonstrated in clinical studies in normal volunteers (13) , in patients on hemodialysis, and in a pediatric population on peritoneal dialysis (2, (14) (15) (16) (17) (18) (19) (20) . In addition to its hypophosphatemic action, SH has the ability to improve the lipid profile in hemodialysis patients (14, 15, 17, 18) .
The present study was designed to evaluate the efficacy of SH compared with AH, which is a classic and more powerful phosphorus binder compared with others, as a phosphorus-binding agent and its influence on serum lipid parameters in adult patients on continuous ambulatory peritoneal dialysis (CAPD) (21, 22) .
PATIENTS AND METHODS

PATIENTS
Thirty (18 male, 12 female; in stable condition for the previous 6 months) of 88 CAPD patients followed in two renal units in our city were included in the study. Demographic characteristics and primary renal disease are given in Table 1 . The exclusion criteria were determined as significant unstable medical conditions, severe anemia (hemoglobin <9 g/dL), heart failure (dyspnea on exertion and at rest and left ventricular ejection fraction <45%), liver dysfunction (AST/ALT >90 UI/mL, INR >1.5, and serum albumin <3.0 g/dL), diabetes mellitus, bowel dysfunction, chronic hepatitis, intestinal surgery, current use of antiarrhythmics or antiseizure drugs, and cancer. None of the patients were on hypolipidemic drugs, inhibitors of hydrochloric acid secretion (H 2 -inhibitors), or vitamin D during the previous month.
All patients underwent the classic CAPD schedule (4 × 2-L exchanges/day). The composition of dialysate solutions used, peritoneal transport characteristics, and peritoneal dialysis dose delivered are shown in Table 2 . Urine output was <100 mL/day. None of the patients were clinically overhydrated (absence of edema and normal blood pressure).
STUDY DESIGN
This study was an open label, randomized crossover trial ( Figure 1 ). All patients underwent a 2-week washout period for phosphorus-binder intake (weeks 0 -2). Only patients with plasma phosphorus concentration >6.0 mg/dL were included in the study. Patients were assigned to receive either SH capsules (15 patients, group I) or AH capsules (15 patients, group II) for 8 weeks (weeks 2 -10, phase A) on the basis of computer-generated random numbers. This first 8-week treatment period was followed by a 2-week (weeks 10 -12) washout period, after which the protocol was repeated using the alternate medication (weeks 12 -20, phase B). Each capsule of SH contained 403 mg of poly(allylamine hydrochloride); each capsule of AH contained 475 mg of aluminum hydroxide.
The initial dose of SH was 2 capsules with each meal if phosphorus was >6.0 and <7.5 mg/dL (>1.94 and <2.42 mmol/L), 3 capsules with each meal if phosphorus was ≥7.5 and <9.0 mg/dL (≥2.42 and <2.91 mmol/L), and 4 capsules with each meal if phosphorus was ≥9.0 mg/dL (≥2.91 mmol/L) (17) .
The initial dose of AH was 2 capsules with each meal if phosphorus was >6.0 and <7. 
BLOOD SAMPLES
Blood samples were taken after a 12-hour overnight fast. Serum levels of calcium (sCa 2+ ), phosphorus (sPO 4 2-), magnesium (sMg 2+ ), alkaline phosphatase (sALP), intact parathormone (iPTH), total cholesterol (T-Chol), triglycerides (Trig), low-density lipoprotein cholesterol (LDL-Chol), lipoprotein(a) [Lp(a)], apolipoprotein A 1 , B, E, (ApoA 1 , ApoB, ApoE), insulin (sIns), and albumin (sAlb) were measured before and at the end of each period during which patients were receiving either SH or AH (weeks 2, 10, 12, and 20).
Serum phosphorus, sMg 2+ , and sALP were measured by a photometric UV test (Olympus 600; Olympus Diagnostica GmbH, Ennis, Ireland). Serum albumin was measured by a photometric BCG method (Olympus 600), sINS by microparticle enzyme immunoassay (MEIA) (AXSYM; Abbott Laboratories, Chicago, Illinois, USA), and iPTH by chemiluminescent immunoassay (Immulite 2000, Diagnostic Products, Los Angeles, California, USA). 
STATISTICAL ANALYSIS
Data are expressed as mean ± SD apart from the median values for Lp(a). For comparisons of variables between groups, we used the t-test. We also assessed whether the results were different in subgroups defined by baseline parameters using analysis of covariance (ANCOVA).
Treatment efficacy was analyzed using the change from the end of the initial washout period (weeks 2 and 12) to the end of the treatment period (weeks 10 and 20). Carryover effect was tested using one sample t-test at the beginning of each period. Analyses were conducted using SPSS 11.0 (SPSS, Inc., Chicago, Illinois, USA). All p values are two tailed. Statistical significance was accepted at p level <0.05.
ETHICS ISSUES
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RESULTS
The average daily doses of SH and AH were 2.0 ± 1.0 g/ day and 1.8 ± 1.2 g/day in phase A, and 1.9 ± 0.8 g/day and 2.1 ± 1.11 g/day respectively in phase B (p = NS). In both phases of the study, the above dose of AH was less than that suggested for short treatment periods (24) .
EFFECT OF SH AND AH ON PHOSPHORUS CONTROL
At the end of the washout period, sPO 4 2-concentrations rose from 5.4 ± 1.3 to 7.4 ± 1.3 mg/dL (1.73 ± 0.41 to 2.39 ± 0.41 mmol/L). At the beginning of treatment in phase A, mean sPO 4 2-concentration in group I was 7.44 ± 1.35 mg/dL (2.38 ± 0.43 mmol/L) (range 6.2 -10.7 mg/dL), and in group II, 7.14 ± 1.23 mg/dL (2.28 ± 0.39 mmol/L) (range 6.4 -10.5 mg/dL). At the end of phase A treatment period, sPO 4 2-fell by 16% in group I and 17.5% in group II. There were no statistically significant differences in changes in sPO 4 2-levels between the two groups (Table 3) . Similarly, in phase B, mean sPO 4 2-concentration in group I was 7.24 ± 1.28 mg/dL (2.31 ± 0.40 mmol/L) and in group II, 7.18 ± 1.35 mg/dL (2.29 ± 0.43 mmol/L). At the end of phase B treatment period, sPO 4 2-fell by 18.6% in group I and 17.1% in group II. There were no statistically significant differences in the reduction of sPO 4 2-concentration between the two groups (Table 3) . Finally, we did not observe any statistically significant changes between groups in sCa 2+ , sMg 2+ , iPTH, sALP, or sINS levels in either phase of the study (Table 4) .
EFFECT OF SH AND AH ON LIPID PARAMETERS
There were important findings in the lipid profile of the CAPD patients receiving SH. Following the washout period of standard phosphorus binders, SH reduced T-Chol by 10.5% ± 9.4% (p < 0.05) and LDL-Chol by 20.1% ± 6.8% (p < 0.001) in group I, phase A. Also, in phase B, SH reduced T-Chol by 11.9% ± 7.2% (p < 0.05) and LDL-Chol by 21.5% ± 2.4% (p < 0.001) in group II (Table 5) . HDL-Chol, Trig, and Lp(a) remained statistically unaffected throughout the study. Moreover, we observed that SH administration influenced levels of serum apolipoproteins. More specifically, increases were observed in ApoA and ApoE; ApoB decreased in both phases of the study (Table 5) .
Administration of AH was not followed by a significant change in serum lipid parameters in either phase of the study (Table 5) .
SIDE EFFECTS
During the study, SH and AH were well tolerated. In the case of SH administration, 1 patient reported dyspepsia, 2 patients constipation (phase A), and 1 patient had nausea (phase B). There were no reports of diarrhea or other gastrointestinal symptoms.
DISCUSSION
The data from this prospective, randomized crossover study indicate that, over a period of 8 weeks, SH effectively lowered serum phosphorus to the same degree as AH. Our results are in agreement with previous studies in hemodialysis patients and a pediatric population on peritoneal dialysis (2, (14) (15) (16) (17) (18) (19) . Those studies showed the ability of SH to lower serum phosphorus levels. Thus, our study suggests that the beneficial effect of SH extends also to adult CAPD patients. Serum calcium, magnesium, alkaline phosphatase, and iPTH were unchanged during the study. These results are in disagreement with previous data, where there was a significant reduction in iPTH using SH in hemodialysis patients (14) (15) (16) ); yet they are in agreement with results in pediatric patients on peritoneal dialysis (19) . Possible explanations for these findings could be the following: (1) CAPD patients may need more than 8 weeks' time for an effect from SH or AH administration on the above parameters, although the reduction in plasma phosphorus concentration was evident; and (2) the loss of vitamin D-binding protein and 1,25-and 24,25-dihydroxycholecalciferol throughout the peritoneal fluids (25) , and the vitamin D-depletive effect of this bile salt binder, which may decrease fatty acid intestinal absorption and therefore interrupt the enterohepatic cycle of vitamin D (26) , may lead to less suppressive action of vitamin D on parathyroid glands. Although, as a phosphorus binder, AH is widely considered a very potent agent, the results of this study show that SH is equally effective in binding serum phosphorus. This effectiveness of SH can be explained: first, the capacity of SH to bind phosphorus is equal to or slightly higher than AH (20, 27) , and second, SH continues to bind phosphorus escaped from the stomach in the small and large intestines (28, 29) .
Lipid abnormalities are common in patients with endstage renal disease and may contribute to the high incidence of atherosclerosis (30, 31) . An important observation of our study was the beneficial effect of SH on T-Chol and LDL-Chol levels compared to AH. Sevelamer hydrochloride binds bile acids, resulting in increased fecal bile acid excretion, thus interrupting the enterohepatic circulation of bile acids. This leads to enhanced hepatic conversion of cholesterol to bile acids (13) . The consequent depletion of hepatic cholesterol stimulates hepatic synthesis and expression of hepatic LDL receptors. This depletion results in reduction of the circulating serum T-Chol and LDL-Chol levels. Therefore, we could suggest that the hypolipidemic effect of SH with the additional anti-inflammatory properties, which have recently been detected in hemodialysis patients, indicate that this drug may be a useful anti-atherogenic agent in the dialysis population (32) .
Although AH has also a strong affinity to bile acids, we did not observe any beneficial effect of AH on lipid parameters, as we would have initially expected. In vitro and in vivo studies have shown that AH has the ability to affect serum lipid parameters to a degree similar to other hypolipidemic agents (33) (34) (35) (36) . However, the hypolipidemic action of AH refers to patients with normal renal function and without proteinuria (36) .
Finally, SH was well tolerated by our patients since only a few reported mild gastrointestinal symptoms. However, among the side effects of the drug, a decrease in serum bicarbonate has been reported in patients on renal replacement therapy (19, (37) (38) (39) (40) (41) . We did not study the influence of SH and AH on acid-base balance in our patients and this could be considered a limitation of our study. However, severe reduction of serum bicarbonate has been observed in only a small proportion of chronic peritoneal dialysis patients (41), while no reduction was observed in a pediatric population on CAPD (19) ; or, the reported metabolic acidosis induced by SH administration in CAPD patients was transient (19, 39) .
In conclusion, SH, a drug free of calcium and aluminum, has a high efficacy in lowering serum phosphorus concentration in CAPD patients. In addition, SH improves serum lipid profile, since it can lower T-Chol and LDLChol levels. Long-term clinical studies are required to determine the efficacy and safety, as well as the possible beneficial effects on cardiovascular morbidity/mortality, of this drug in CAPD patients.
